7:14AM Boston Scientific Anemic For Now -- BWeek (BSX) 33.60: BusinessWeek's Inside Wall St section highlights Boston Scientific when has fallen since its summer recall of 100,000 coronary stents and since its lowered Q4 guidance. But John Maloney of M&R Capital Mgmt, which owns stock, says that BSX -- a maker of surgical devices for cardiology, oncology, and urology -- is too undervalued to ignore. With its leadership in stents (70% of the market vs. 30% for Johnson & Johnson (JNJ)) and its "rich pipeline" of other products, BSX shouldn't be trading so low, he argues. "It is the cheapest in the medical-device group," he says, selling at only 15x 2005 EPS, and 13.6x 2006. His 12-to-18-month target: $50 -- or 20x his 2006 estimate. BSX may lose market share in stents, he says, as competition heats up, but it will remain No. 1. Non-stent products, such as tools for cardiac surgery, will offset any loss.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat